Notice of Award of a Single-Source Cooperative Agreement To Fund the Kazakhstan Scientific Center for Dermatology and Infectious Diseases (KSCDID), 9622 [2022-03629]
Download as PDF
<![CDATA[
9622
Federal Register / Vol. 87, No. 35 / Tuesday, February 22, 2022 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Award of a Single-Source
Cooperative Agreement To Fund the
Kazakhstan Scientific Center for
Dermatology and Infectious Diseases
(KSCDID)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), located
within the Department of Health and
Human Services (HHS), announces the
award of approximately $500,000, for
Year 1 of funding to the Kazakhstan
Scientific Center for Dermatology and
Infectious Diseases (KSCDID). The
award will reduce new HIV infections
and AIDS deaths in Kazakhstan through
rapidly expanding prevention, testing,
care, and effective treatment services to
people living with HIV (PLHIV).
Funding amounts for years 2–5 will be
set at continuation.
DATES: The period for this award will be
September 30, 2022 through September
29, 2027.
FOR FURTHER INFORMATION CONTACT:
Patrick Nadol, Center for Global Health,
Centers for Disease Control and
Prevention, 171 Prospect Mira, Bishkek,
720016, Kyrgyz Republic, Telephone:
800–232–6348, E-Mail: pen5@cdc.gov.
SUPPLEMENTARY INFORMATION: The
single-source award will implement
prevention, testing, care and treatment,
laboratory, and strategic information
activities in Kazakhstan. KSCDID is in a
unique position to conduct this work, as
it is the leading organization
implementing the National HIV program
in Kazakhstan; it will lead and sustain
the national HIV services for prevention,
testing, care, treatment, and strategic
information according to international
standards to achieve epidemic control
and ensure resilient and sustained
health care systems. KSCDID develops
policy and regulations, conducts
prevention and testing activities,
coordinates care and treatment, and is
responsible for quality assurance of
laboratory services.
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
Summary of the Award
Recipient: Kazakhstan Scientific
Center for Dermatology and Infectious
Diseases (KSCDID).
Purpose of the Award: The purpose of
this award is to reduce new HIV
infections and AIDS deaths in
VerDate Sep<11>2014
19:42 Feb 18, 2022
Jkt 256001
Kazakhstan through rapidly expanding
prevention, testing, care, and effective
treatment services to PLHIV.
Amount of Award: The approximate
year 1 funding amount will be $500,000
in Federal Fiscal Year (FFY) 2022 funds,
subject to the availability of funds.
Funding amounts for years 2–5 will be
set at continuation.
Authority: This program is authorized
under Public Law 108–25 (the United
States Leadership Against HIV AIDS,
Tuberculosis and Malaria Act of 2003).
Period of Performance: September 30,
2022 through September 29, 2027.
Dated: February 15, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2022–03629 Filed 2–18–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–22–1268]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Drug Overdose
Surveillance and Epidemiology (DOSE)’’
to the Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on April 26, 2021, to obtain
comments from the public and affected
agencies. CDC received four comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Drug Overdose Surveillance and
Epidemiology (DOSE) (OMB Control No.
0920–1268, Exp. 8/31/2022)—
Revision—National Center for Injury
Prevention and Control (NCIPC),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
In 2020, a total of 91,799 drug
overdose deaths occurred,
corresponding to an age-adjusted rate of
28.3 per 100,000 population and a 31%
increase from the 2019 rate (21.6). From
2013 to 2019, the synthetic opioidinvolved death rate increased 1,040%,
from 1.0 to 11.4 per 100,000 ageadjusted (3,105 to 36,359). The
psychostimulant-involved death rate
increased 317%, from 1.2 (3,627) in
2013 to 5.0 (16,167) in 2019. Non-fatal
overdoses are on the rise as well;
Emergency Department (ED) data from
DOSE indicates increases from 2018 to
present. In response to the growing
severity of the opioid overdose
epidemic, the U.S. government declared
the opioid overdose epidemic a public
health emergency on October 26, 2017.
The opioid overdose epidemic is one of
the top priorities of the U.S. Department
of Health and Human Services (HHS). In
E:\FR\FM\22FEN1.SGM
22FEN1
]]>Agencies
[Federal Register Volume 87, Number 35 (Tuesday, February 22, 2022)]
[Notices]
[Page 9622]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03629]
[[Page 9622]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Award of a Single-Source Cooperative Agreement To Fund
the Kazakhstan Scientific Center for Dermatology and Infectious
Diseases (KSCDID)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), located
within the Department of Health and Human Services (HHS), announces the
award of approximately $500,000, for Year 1 of funding to the
Kazakhstan Scientific Center for Dermatology and Infectious Diseases
(KSCDID). The award will reduce new HIV infections and AIDS deaths in
Kazakhstan through rapidly expanding prevention, testing, care, and
effective treatment services to people living with HIV (PLHIV). Funding
amounts for years 2-5 will be set at continuation.
DATES: The period for this award will be September 30, 2022 through
September 29, 2027.
FOR FURTHER INFORMATION CONTACT: Patrick Nadol, Center for Global
Health, Centers for Disease Control and Prevention, 171 Prospect Mira,
Bishkek, 720016, Kyrgyz Republic, Telephone: 800-232-6348, E-Mail:
[email protected].
SUPPLEMENTARY INFORMATION: The single-source award will implement
prevention, testing, care and treatment, laboratory, and strategic
information activities in Kazakhstan. KSCDID is in a unique position to
conduct this work, as it is the leading organization implementing the
National HIV program in Kazakhstan; it will lead and sustain the
national HIV services for prevention, testing, care, treatment, and
strategic information according to international standards to achieve
epidemic control and ensure resilient and sustained health care
systems. KSCDID develops policy and regulations, conducts prevention
and testing activities, coordinates care and treatment, and is
responsible for quality assurance of laboratory services.
Summary of the Award
Recipient: Kazakhstan Scientific Center for Dermatology and
Infectious Diseases (KSCDID).
Purpose of the Award: The purpose of this award is to reduce new
HIV infections and AIDS deaths in Kazakhstan through rapidly expanding
prevention, testing, care, and effective treatment services to PLHIV.
Amount of Award: The approximate year 1 funding amount will be
$500,000 in Federal Fiscal Year (FFY) 2022 funds, subject to the
availability of funds. Funding amounts for years 2-5 will be set at
continuation.
Authority: This program is authorized under Public Law 108-25 (the
United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act
of 2003).
Period of Performance: September 30, 2022 through September 29,
2027.
Dated: February 15, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2022-03629 Filed 2-18-22; 8:45 am]
BILLING CODE 4163-18-P
